This article focuses on results of a study headed by Dr. Jack D. Sobel, professor and chief of the Division of Infectious Diseases at the WSU School of Medicine. The study found that Pfizer's Vfend antifungal treatment is an effective treatment for patients with candidemia, an often-fatal hospital-acquired bloodstream infection. "Because of Vfend's broad spectrum of activity against infections caused by yeasts and moulds, it is a good first-choice treatment option for immunocompromised patients who are at risk for those types of infection," Sobel said. Results of the study also appeared in several other online medical newsletters.